



Invitation to subscribe for shares in Eevia Health

Rights Issue

The following summary of the Memorandum (the "Teaser") is not an offer but is to be seen as an introduction to Eevia Health PLC's ("Eevia" or the "Company") Memorandum (the "Memorandum") and does not necessarily contain all information for an investment decision to be made. The investor is advised to consult the Memorandum, which is available on Eevia's website (www.eeviahealth.com), before making an investment decision to take note of the potential risks associated with the decision to invest in the securities.

The Offer in summary

Subscription period:	November 1-15, 2022 in Sweden and November 1-17 in Finland.
Subscription price:	SEK 1,5 per share, and EUR 0,133 per share.
Volume of issuance:	The offer comprises a maximum of 14 376 015 shares, corresponding to approx. SEK 21,6 million.
Record date:	Record date of the Offer at both Euroclear Sweden and Euroclear Finland is 27 October 2022. The last day of trading with shares in the Company including Subscription Rights is 25 October 2022. The first day of trading with shares in the Company without Subscription Rights is 26 October 2022.
Preferential right:	Parties who on the record date 27 October 2022, were listed in the stock register as shareholders of Eevia have preferential right to subscribe for shares in the rights offering in relation to their previous shareholdings, whereby one (1) old share entitles to one (1) subscription right. Ten (10) such subscription rights entitle subscription of nine (9) new shares. The general public in Sweden is also invited to subscribe for shares in the rights issue, without preferential.
Number of shares prior to the rights issue:	15 973 356
Trading period of subscription rights:	Trading in Subscription Rights (trading symbol EEVIA_TR, ISIN: SE0019019621) will take place on Spotlight Stock Market from the 1 November 2022, until the 10 November 2022.
Valuation in the offering (Pre-money):	Approx. SEK 30,7 million.
Trading period of BTA:	Trading in BTA's (trading symbol EEVIA_BTA, ISIN: SE0019019639) will take place on Spotlight Stock Market from 1 November, 2022 until the Offer Shares have been registered with the Finnish Trade Register. Subscribed shares are entered as BTA in the securities depository account until Offer Shares have been registered with the Finnish Trade Register, which is expected to take place in the beginning of December 2022.
Pre-subscription commitments and underwriting commitments:	The Company received, on October 20, 2022, legally binding pre-subscription commitments of approximately SEK 9,3 million, which corresponds to approximately 43 percent of the Offer volume, and underwriting commitments of approximately SEK 8,3 million, which corresponds to approximately 39 percent of the Offer volume, resulting in 82 percent in total.
Dilution:	The number of shares in Eevia will, provided that the Offer is fully subscribed for, increase by 14 376 015 shares from 15 973 356 shares to 30 349 371 shares implying a dilution of 47 percent for existing shareholders who do not participate in the Offer.
Trading platform:	Eevia Health Oy's shares are listed on Spotlight Stock Market.
ISIN-code for the shares:	FI4000496658

Important information

The following summary of the Memorandum (the "Teaser") is not an offer but is to be seen as an introduction to Eevia Health PLC's ("Eevia" or the "Company") Memorandum (the "Memorandum") and does not necessarily contain all information for an investment decision to be made. The investor is advised to consult the Memorandum, which is available on Eevia's website (www.eeviahealth.com), before making an investment decision to take note of the potential risks associated with the decision to invest in the securities. Eevia Health PLC, organizational number (Finnish business identity code) 2825194-4.

Eevia in brief

Eevia addresses global health challenges with bioactive extracts from natural, plant-based raw materials, that have clinically documented health benefits. Standardized plant extracts, with well-researched positive effects for human health, are sold B2B as ingredients to supplements, food, and cosmetic brands globally. Founded in 2017, Eevia's sales have grown with an average Q-on-Q growth of 25 percent to EUR 6.7m in total for the full year of 2021. Growth has continued in 2022 and the sales of the first half-year amounted to EUR 3.5m. Eevia operates a distributor business model in three continents and with indirect customers in 16 countries.

Eevia's product line includes branded ingredients based on extracts of organic bilberries, lingonberries, elderberries, Chaga mushrooms, and pine bark, carefully manufactured in Eevia's green chemistry extraction facility in Finland. The plant extracts are developed and produced from sustainable raw material sources, often underutilized raw materials abundantly available in the Nordic forests. The elderberries are also imported from Central Europe.

The strategic focus of the Company is two-fold. One is the development of differentiating virtues of Eevia's branded ingredient products, such as "natural", "organic", "wild harvested" and sustainable". A continuous effort to expand the value proposition to customers through improved substance related to these "virtues", will increase Eevia's competitiveness. The other focus is the selection of key health indications, through which Eevia aims to compete with scientific substantiation of health effects. Currently, Eevia has focused on immune modulation with its elderberry and Chaga mushroom-derived extracts, low-grade inflammation with its pine bark-derived extracts, and metabolic conditions with its bilberry and lingonberry-derived extracts.

In the long-term strategy and R&D pipeline, the Company will, in addition to its current practices, work with age-related health problems stemming from decline in important biological processes within the cells, such as the autophagy response. The Company is in the early stages of developing new innovative ingredients addressing age-related health problems, such as Retinari™ targeting age-related macular degeneration (AMD). The resulting product will be sold B2B as a branded ingredient.

In the research, product development, and sales of the products, Eevia works with world-class partners. Carefully selected distributors, such as Barrington Nutritionals (US) and Ingredient Plus (Australia), Natural Ingredients (France) represent Eevia in targeted markets (USA, Europe, and Australia) and expands the Company's marketing and sales reach to world-class brands.

The Company stands out internationally with its narrow focus on a few health indications, natural raw materials, organic certification of all products (also US NOP certificates issued by Finnish authorities on license from US FDA), and a strong focus on sustainability, transparency, authenticity, and purity of the supply chain and raw materials.



Background and motive

Since the formation in 2017, the Company has built the processes, production protocols, and procedures for organic products to international clients. Demand has been strong, and during prior periods, the Company has had to reject multi-year, multi-million-euro sales opportunities, due to insufficient production capacity and inability to invest in such capacity, due to capital insufficiency. After raising capital in recent years, including in the Company's IPO last year, the Company was able to invest in increased capacity. The capacity and investment projects are now largely complete, and Eevia is currently in a position to take on significant new business opportunities.

While the investment projects are largely completed, Eevia needs further equity funding for working capital and general corporate purposes to be in a position to take on significant new business opportunities and to continue developing the organization. The Board of Directors has therefore decided to pursue a rights issue directed initially at the Company's existing shareholders to generate the capital needed to expand.

Accordingly, the Company now conducts a rights issue taking place on Spotlight Stock Market. The rights issue ("The Offer") may provide the Company with SEK 21,6 million before deduction of transaction costs, which amounts to approximately SEK 3 million. The Offer will be implemented with preferential rights for existing shareholders. The use of the proceeds from the Offer is described in more detail below.

Use of proceeds from the Offer:

The majority of the funds will be used to increase the Company's net working capital, which will enable Eevia to undertake increase in raw material inventory for bilberries and other materials, which again may be needed to serve some large prospects in the pipeline.

Eevia also needs to increase focus on developing the organization in order to facilitate continued growth. This will involve building stronger marketing, regulatory, product management and sales management teams.

A portion of the proceeds from the Offer will be used for some investments to improve certain functions, connected to waste streams and energy consumption.

Rapidly growing market

Eveia's products are marketed and sold as part of the *global plant extracts market*, which is one of the larger segments of the broader *global nutraceutical ingredients market*. According to forecasts, both the global nutraceutical and plants extracts markets are going to witness robust growth in upcoming years.

The global market for nutraceuticals will grow at 7.5 percent CAGR, according to a recent study by PMMI Business Intelligence, from a USD 241b market in 2019 to USD 373b in 2025. The key market drivers of the global nutraceutical market are expected to be the changing consumer preferences towards nutraceutical diets and changing demographics along with increase in R&D activity.

Similarly, the global plant extracts market on producers' level was estimated to be valued at USD 23.7b, and projected to reach USD 59.4b by 2025, at a CAGR of 16.5 percent from 2019 to 2025. The rising awareness regarding the side-effects of synthetic flavors and health benefits offered by phytomedicines and herbal extracts have significantly fueled the global plant extracts market historically. Further, due to the growth in R&D activities in plant extracts market and increase in popularity of convenience food, there has been a growing need for plant extracts in the food and beverage industry. The same factors are expected to drive the global plants extracts market in the upcoming years.


Global Nutraceutical Ingredients Market (USD Billion)

7,5% CAGR



Plant Extracts Market (USD Billion)

16,5% CAGR



CEO Stein Ulve comments

We all watched as the world changed significantly in less than a year. Consumers in our key markets are wary, inflation rampant, economies veering, and retailers are reorganizing shelves. However, Eevia Health is a small fish in a big pond. Our fate is largely in our own hands. While we are, of course, affected by the world around us, our future does not directly correlate with how retail sales are fluctuating. Rather, our performance over time will mainly be driven by how well we compete in the large B2B ingredient markets and the success we achieve in bringing in new customers and increase our still tiny market share globally.

We expect growth in the nutraceutical markets going forward. Major players are cautious but with a positive outlook. The order desk registered several significant sales orders in June for Feno-Myrtillus®, our branded bilberry ingredient with a high concentration (36%) of anthocyanins. We booked an order for a new organic lingonberry product with gum acacia as the carrier, delivered to an Australian customer just after the end of the quarter.

Eevia Health has started reaping the rewards of significant efforts and investments in 2021 and 2022. I am pleased that production performance and product output have improved substantially in 2022. We caught up with backlogged sales contracts. Operational improvements have trickled through to our financial results. I am proud of the team's efforts and stamina in seeking sustainable profitability and continued growth.

We now have new manufacturing capacity and systems for improved performance control. The keys to our profitability are correct quality materials, robust manufacturing yields, throughput and productivity. The gross margin was 35% in Q2-22. We also reached positive cash flow from operations.

The financial target of MEUR 25 in sales revenues for 2024 remains steady. Reaching it will require strong product positioning and efficient handling of our sales pipeline over the next eight quarters. We must develop our overall value proposition and competitive edge. The way the world is spinning underpins the need to focus on supply chain reliability, sustainability, environmental footprint, organic certification, and providing documented health solutions relevant to consumers.

For profitability, more important than revenue, is the gross profit. Improving the raw material margin and use of other variable resources, are fundamental drivers for our improvement in profitability. In addition, we are looking at more efficiently using all resources. Besides raw material efficiencies, key internal cost improvement targets are to secure efficient use of energy, water, and, importantly, competent human resources. Similarly, we have a exiting path to valorizing currently non-utilized side streams such as fruit sugars and berry fibers.

Eevia Health is now better positioned to accept new, larger sales contracts for our main products going forward. We will take a much more forward leaning approach and find new ways of promoting our ingredient boutique offering. In subsequent quarters we aim to launch new innovative ingredients, such as our game-changing eye health product candidate Retinari™, to drive rapid growth also beyond 2024.

The Management team maintains a profitability focus, but we also strive to continue the growth path and placing Eevia Health as a distinct brand in the global nutraceutical market.

Stein Ulve

CEO, Eevia Health Plc
28 October, 2022



Strategy and business targets and milestones

2022

Strategic focus

- Strengthen the competitive position on key products with new features and documentation. Sharpening the focus on need states and conditions and same for our value proposition.
- Increase the incoming pipeline of sales opportunities through more forward leaning inbound marketing efforts.
- Start valorizing side streams.
- Improve customer service level and achieve high customer satisfaction.

Tactical focus

- Consolidate the customer/sales portfolio with 1 large customer, 2–4 medium sized customers and some smaller customers.
- Stabilize the Company with high productivity, consistent yields and profitability performance, strong liquidity management, high-capacity utilization, and strong project management.

2023

Strategic focus

- Entrench key products with unique features and create a powerful value proposition.
- Expand sales portfolio to 5–10 large customers.
- Develop clinical substantiation on strategic R&D products.

Tactical focus

- Strong handling of incoming sales pipeline and expansion of distribution network.
- Drive productivity, yields and cost savings for consistent profitability performance.
- Robust and competitive products management through new Product managers.

2024

Financial targets

Net sales *Exceeding*

EUR **25M**

Gross margin *Exceeding*

40%

EBITDA margin *Exceeding*

15%

Terms and conditions

The Offer

The Board of Directors of Eevia decided on October 20, 2022, based on authorization from the Extraordinary General Meeting held on October 11, 2022, in accordance with the shareholders' pre-emptive subscription right, to issue up to 14 376 015 new shares in the Company for subscription by the Company's shareholders (the "Offer Shares") (the "Offer"). The subscription period starts in Sweden on November 1, 2022 and ends on November 15, 2022. The subscription price is SEK 1,50 (EUR 0,133) per share and the total issue proceeds are at maximum SEK 21,6 million before deduction of transaction related costs.

Eevia will give all shareholders registered in Eevia's shareholder register maintained by Euroclear Finland Oy ("Euroclear Finland") and Euroclear Sweden AB ("Euroclear Sweden") one (1) book-entry subscription right (the "Subscription Right") per each share held on the Offering record date of October 27, 2022. Ten (10) Subscription Rights entitle their holder to subscribe for nine (9) Offer Shares. Fractions of Offer Shares are not assigned, and a single Subscription Right may not be exercised only partially. The Subscription Rights will be registered in shareholders' book-entry accounts in the book-entry system maintained by Euroclear Finland approximately on October 28, 2022 and in the book-entry system maintained by Euroclear Sweden approximately on October 31, 2022. The Subscription Rights can be freely assigned, and they will be traded on Spotlight (trading symbol EEVIA_TR, ISIN: SE0019019621) during November 1-10, 2022. If a Company share entitling to a Subscription Right is subject to a pledge or another such restriction, the Subscription Right may not be exercisable without the consent of the pledgee or other rights holder.

The Finnish shareholders need to transfer their shares to the book-entry system maintained by Euroclear Sweden before record date of the Offer in order to be able to trade on the Subscription Rights and the BTA (interim shares) on Spotlight.

Record date

Record date of the Offer at both Euroclear Sweden and Euroclear Finland is October 27, 2022. The last day of trading with shares in the Company including Subscription Rights is October 25, 2022. The first day of trading with shares in the Company without Subscription Rights is October 26, 2022.

Subscription price

The subscription price, determined by the Board of Directors, is SEK 1,50 and EUR 0,133 per share (the "Subscription Price"). The Subscription Price for the Offer Shares will be recorded in the reserve for invested unrestricted equity. The Subscription Price includes a normal pre-emptive rights issue discount. The Subscription Price is approximately 31 percent lower than the volume-weighted average share price ("VWAP20") during the latest 20 trading days preceding October 26, 2022 on Spotlight Stock Market Sweden.

No brokerage fee will be charged.

Subscription period

The subscription period for the Offer Shares (the "Subscription Period") will commence on November 1, 2022 at 09:30 Finnish time (08:30 Swedish time) and is expected to end on November 15, 2022 at 16:30 Finnish time (15:30 Swedish time) in Sweden and on November 17, 2022 at 16:30 Finnish time (15:30 Swedish time) in Finland.

The Company may, at its sole discretion, extend the Subscription Period. The Subscription Period may be extended once or several times. Any extensions of the Subscription Period will be announced by way of a company release before the end of the Subscription Period.

If the Subscription Period is extended, the allocation date, the payment due dates and the dates of delivery of Offer Shares will be changed accordingly.

Subscription locations, account operators, custodians and nominees may require their customers to submit subscription orders on a certain day prior to the start of trading on the Subscription Rights or before the Subscription Period ends.

Subscription locations

The following function as subscription locations:

- a) In Finland, custodians, and account operators and
- b) In Sweden, Partner Fondkommission AB's website at www.partnerfk.com and Partner Fondkommission AB's premises at Lilla Nygatan 2, Sweden (info@partnerfk.se, tel. +46 (0)31-761 22 30).

Dilution

The number of shares in Eevia will, provided that the Offer is fully subscribed for, increase by 14 376 015 shares from 15 973 356 shares to 30 349 371 shares implying a dilution of 47 percent for existing shareholders who do not participate in the Offer.

Costs imposed on investors

There are no costs imposed on investors by the Company. However, investors will bear customary transaction and handling fees required by their account-holding banks.

Preferential right for subscription

Parties who on the record date October 27, 2022, were listed in the stock register as shareholders of Eevia have preferential right to subscribe for shares in the rights offering in relation to their previous shareholdings, whereby one (1) old share entitles to one (1) subscription right. Ten (10) such subscription rights entitle subscription of nine (9) new shares. The general public in Sweden is also invited to subscribe for shares in the rights issue, without preferential.

Subscription rights

Trading with subscription rights

Trading in Subscription Rights will take place on Spotlight Stock Market from the 1 November, 2022, until the 10 November, 2022. Shareholders should immediately contact their bank or other nominee with the necessary authority to carry out the purchase or sale of Subscription Rights. Subscription Rights that are acquired during the above-mentioned trading period provide, the same right to subscribe for Offer Shares as shareholders with Subscription Rights based on their shareholdings in the Company on the record date. Subscription Rights must be exercised no later than on the November 15, 2022 or sold no later than the November 10, 2022, in order to not become void or lose their value.

Pre-subscription commitments and underwriting commitments

The Company received, on October 20, 2022, legally binding pre-subscription commitments of approximately SEK 9,3 million, which corresponds to approximately 43 percent of the Offer volume, and underwriting commitments of approximately SEK 8,3 million, which corresponds to approximately 39 percent of the Offer volume, resulting in 82 percent in total. Subscription commitments and underwriting commitments have not been secured through advanced transaction, bank guarantee or similar. A cash premium compensation of twelve (12) percent if paid in cash and fifteen (15) percent if received in shares is received for entering the underwriting commitment and is paid from the Company to each of the underwriters after the Offer is finalized.

Subscription of shares

Shareholders directly registered in Euroclear

Shareholders or representatives of shareholders, who on the record date October 27, 2022, were registered in Eevia's shareholder register maintained by Euroclear Finland or Euroclear Sweden, receives a preprinted paying slip (account statement), the subscription form "Subscription with subscription rights", the subscription form "Subscription without subscription rights" and a folder containing the terms, conditions for the Offer with referral to the memorandum and a money laundry form. The information can be downloaded at Partner Fondkommission's web page (www.partnerfk.se) or at the web page of the Company (www.eeviahealth.com). Shareholders who



are included in the separate list of pledgees and others in relation to the Euroclear system do not receive information and will be notified separately. An account notice, which declares the delivery of Subscription Rights on the shareholders' book-entry account, are not distributed.

Subscription with the support of Subscription Rights shall be made by simultaneous cash payment no later than November 15, 2022, at 15:30 Swedish time. Subscription by payment must be made either with the prepaid payment slip attached to the issuance statement or by payment instructions on the special subscription form in accordance with the following two options:

1. Preprinted paying slip (account statement)

If all Subscription Rights allotted on the record date shall be exercised, only the preprinted paying slip shall be used as documentation for subscription by way of cash payment. The subscription form "Subscription with subscription rights" shall not be used in this case. No additions and changes may be made in the text printed on the subscription form. Note that the subscription is binding.

2. Subscription form – "Subscription with subscription rights"

If a different number of Subscription Rights than what is stated on the pre-printed paying slip shall be exercised, for example, if Subscription Rights are acquired or sold, the subscription form "Subscription with subscription rights" shall be used for subscription by means of cash payment. The subscriber must state on the subscription form the number of Subscription Rights being exercised, the number of Offer Shares they are subscribing for, and the amount that is being paid. If the payment is made in any way other than with the attached payment slip, the securities account must be indicated as a reference. Incomplete or incorrectly filled out subscription forms may be disregarded. The subscription form "Subscription with subscription rights" can be downloaded at Partner Fondkommission's web page (www.partnerfk.se). A completed subscription form must, in connection with cash payment, be sent to, and received by Partner Fondkommission no later than the November 15, 2022 at 15:30 Swedish time on the contact details stated below. It is only allowed to submit one (1) subscription form per subscriber. In case several subscription forms are submitted, only the last received will be considered. The subscription is binding.

Partner Fondkommission

Subject: Eevia Health Plc

Lilla Nygatan 2, 411 09 Göteborg

Info@partnerfk.se

Shareholders registered with a nominee

Shareholders whose holdings of shares in the Company are nominee registered with a bank or other trustee do not receive a preprinted paying slip or subscription form. A teaser and the Memorandum can be found on the Company's website (www.eeviahealth.com). Subscription and payment should instead be in accordance with instructions from the respective bank or trustee. Please note that in the case that the use of Subscription Rights takes place via a bank or a trustee, this should be done early in the Subscription Period, as the respective bank or trustee may set different deadlines for the last subscription date.

Subscription of shares with subscription right

Subscription of Offer Shares is done by filling out and signing the subscription form, which must be Partner Fondkommission at hand no later than November 15, 2022 at the following address or by email. Please note that subscriptions placed are binding and irrevocable.

Subscription forms sent by mail must be sent in time before the last day in the Subscription Period. It is only allowed to submit one (1) subscription form per subscriber. In case several subscription forms are submitted, only the last received will be considered. Incomplete or incorrectly completed subscription forms may be disregarded. No additions and changes may be made in the text printed on the subscription form.

Subject: Eevia Health Plc
Partner Fondkommission AB
Lilla Nygatan 2
411 09 Göteborg, Sweden

Phone: +46 (0)31-761 22 30
E-post: info@partnerfk.se (scanned subscription form)

Subscribers must have an account directly registered in Euroclear Sweden's system or a securities account with a bank or other nominee to whom the delivery of shares can take place. Subscribers who do not have a VP account or securities account must open such accounts with Euroclear Sweden or with a bank or nominee before submitting the subscription form to Partner Fondkommission. Note that this may take some time.

Subscription forms and this Memorandum will be available on Partner Fondkommission's website (www.partnerfk.se) and at the Company's website (www.eeviahealth.com).

Subscription of shares without subscription rights

An application for subscription for Offer Shares without Subscription Rights is to be made on the form "Subscription without subscription rights" available for downloading from Partner Fondkommission's website (www.partnerfk.se), at the website of the Company (www.eeviahealth.com), and at Spotlight Stock Market's website (www.spotlightstockmarket.com).

Nominee-registered shareholders, requesting subscription of shares without Subscription Rights, must coordinate such a subscription with the account-holding bank or broker in accordance with instructions from the respective account-holding bank or broker, or if shares are registered at several different nominee-registered accounts, from each of these account-holding banks or brokers. Subscription can also be made on the form "Subscription without subscription rights". Note that anyone who has a custody account or account with specific rules for securities transactions, such as an investment savings account (ISK) or equity insurance account (KF), must check with the bank/nominee for the account, if, and if so how, the subscription of Offer Shares within the framework for the Offer is possible. In this case, the subscription must be made in agreement with the bank/nominee responsible for the account.

Incomplete or incorrectly filled in subscription forms may be disregarded. It is only allowed to submit one (1) subscription form "Subscription without Subscription Rights." If more than one such subscription form is submitted, only the one last received will be considered, and other such subscription forms will thus be disregarded. The subscription form must be Partner Fondkommission at hand no later than November 15, 2022, at 15:30 Swedish time. The subscription is binding.

Allocation of shares

If not all Offer Shares in the Offer are subscribed for with Subscription Rights, the Board of Directors shall decide on allocation of the Offer Shares within the limits of the maximum amount of the Offer to shareholders or other investors that have subscribed for shares without Subscription Rights.

Allocation of shares which are subscribed for without Subscription Rights shall first be done to shareholders or other investors who have also subscribed for Offer Shares by exercising Subscription Rights, regardless of if the subscriber was a registered shareholder on the record date or not. In case that allocation of Offer Shares cannot fully be provided in accordance with subscriptions without Subscription Rights, allocation shall be made in relation (pro rata) to the quantity of Subscription Rights exercised for subscription of Offer Shares in the Offer, and to the extent this is not possible, by drawing of lots. Secondly, allocation of Offer Shares which are subscribed for without Subscription Rights shall be done to other investors than the above mentioned, who have subscribed for Offer Shares without Subscription Rights. In case that allocation of Offer Shares cannot fully be provided in accordance with subscriptions without Subscription Rights, allocation shall be made in relation (pro rata) to the amount of subscribed for Offer Shares without Subscription Rights in the Offer, and to the extent this is not possible, by drawing of lots. Thirdly, the allocation of Offer Shares shall be made to the underwriters in proportion to the size of the underwriting commitments made, and to the extent this is not possible, by drawing of lots.

Notification of allocation

Notification of allotment of Offer Shares without Subscription Rights will be made via a settlement note containing payment instructions for allotted Offer Shares. Settlement notes are expected to be sent out as soon as possible after the Subscription Period, and payment must be made in accordance with the payment instructions on the settlement note. Payment must be made to a Swedish account in no later than two (2) days after transmitted settlement note. Note that payment for any allotted Offer Shares will not be drawn from the specified book-entry account. If payment or confirmation of payment is not made at the time stated on the settlement note, there may be a risk that allocated Offer Shares will not be delivered in time for the first trading date of Offer Shares or a risk that the shares are transferred to another party. Should the sale price of such transfer be below the subscription price of this Offer, the original subscriber who acquired the Offer Shares may be responsible for all, or part of the difference. The Board of Directors retains the right to prolong the payment period. Shareholders or other investors that are not allotted any Offer Shares will not receive any notification.

Subscription above EUR 15,000

If the subscription amounts to, or exceeds, EUR 15k a money laundering form shall be filled out and sent to Partner Fondkommission in accordance with the Swedish Act (2017:630) on measures against money laundering and financing of terrorism. Please observe that Partner Fondkommission cannot distribute any securities, even if payment have been received, before the money laundering form has been received by Partner Fondkommission.

Shareholders residing outside of Finland and Sweden

Shareholders who reside outside of Finland and Sweden (with the exception of shareholders residing in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan and other countries in which participation in the Offer requires supplementary memorandum, registrations or actions other than those under Swedish law) who would be entitled to Subscription Rights in the Offer can contact Partner Fondkommission for further information about subscription and payment. Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan and other countries where participation requires supplementary memorandum, registrations or actions other than those under Swedish law, the Offer to subscribe for Offer Shares is not directed at persons or others with registered address in any of these countries.

Shareholders and investors residing in Finland or other countries outside of Sweden

Shareholders and other investors not residing in Finland or Sweden who can subscribe for Offer Shares in the Offer are notified that subscription and payment of Offer Shares through a non-Swedish bank or broker may be associated with additional costs or fees which the shareholder or investor will be charged by the specific bank or broker. Furthermore, delivery and account holding of shares via a non-Swedish bank or broker may be associated with additional costs or fees, which the shareholder or investor will be charged by the specific bank or broker.

Paid and subscribed for interim shares ("BTA")

Subscription based on Subscription Rights is registered with Euroclear Finland and Euroclear Sweden as soon as feasible, which normally means a few banking days after payment is made. Thereafter, the subscriber will receive a securities depository account notification confirming that the registration of Paid Subscribed Shares ("BTA") has occurred in the subscriber's securities depository account. Subscribed shares are entered as BTAs in the securities account until the Offer Shares have been registered with the Finnish Trade Register.

Shareholders who have their holdings in a custodial account at a bank or brokerage firm will receive information from their respective custodians.

Trading in BTA

Trading in BTA's (trading symbol EEVIA_BTA, ISIN: SE0019019639) will take place on Spotlight Stock Market from November 1, 2022 until the Offer Shares have been registered with the Finnish Trade Register. Subscribed shares are entered as BTA in the securities depository account until Offer Shares have been registered with the Finnish Trade Register, which is expected to take place in the beginning of December 2022.

Delivery of shares

The Offer Shares are expected to be registered with the Finnish Trade Register (the "Trade Register") on or about November 30, 2022. The Offer Shares are expected to be delivered to the subscribers in the Offer through Euroclear Finland on or about December 2, 2022 and Euroclear Sweden on or about December 9, 2022.

The shares of the Company are registered in the electronic book-entry securities system maintained by Euroclear Finland. The Company and its shares will have their primary registration in the book-entry register of Euroclear Finland. Further, the shares are registered in the corresponding Swedish book-entry securities system maintained by Euroclear Sweden.

Publication of the outcome of the Offer

As soon as possible after the Subscription Period has ended, the Company will publish the outcome of the Offer. The publication is scheduled to November 22, 2022 and will be made through a press release, which will be available on the Company's website.

Trading in the share

The shares of the Company are listed on Spotlight Stock Market. The shares are traded under the ticker "EEVIA" and have the ISIN-code FI4000496658. The Offer Shares will be admitted to trading in connection with that conversion of BTA to (regular) shares occurs.

Right to dividend

The Offer Shares entail the right to any dividend for the first time on the first record date of dividend which occurs after the Offer Shares are registered at the Trade Register. The Offer Shares carry the same right to dividend as existing shares.

**Shareholder rights**

The shareholders' right to dividend, voting right, preferential right of shares is governed by both the Company's articles of association (available at the webpage of Eevia), as well as the Finnish Companies Act.

Applicable law

The terms and conditions of the Offer shall be governed by and construed in accordance with Finnish law.

Shareholder's register

The Company is a Euroclear Sweden-affiliated company. The Company's share register with information about shareholders is handled and accounted for by Euroclear Finland Oy, Urho Kekkosen katu 5 C, 00100 Helsinki, Finland and Euroclear Sweden AB, Klarabergsviadukten 63, 111 64 Stockholm, Sweden.

Financial adviser and issuer agents

Partner Fondkommission is the financial adviser and issuer agent in connection with the Offer in Sweden and OP Bank is the issuer agent in Finland.

Other

All shares that are offered through this Offer will be newly issued. There are no natural or legal persons offering to sell or loan shares in this Offer.

Questions regarding the Offer may be addressed to Eevia Health Plc, CEO Stein Ulve, Phone: +358 400 22 5967 E-mail: stein@eeviahealth.com or to Partner Fondkommission AB, Phone: +46 (0)31-761 22 30, E-mail: info@partnerfk.se.

How to subscribe

Terms and conditions

For each held share on the record date of the Offer, you will receive one (1) Subscription Right. Ten (10) Subscription Rights entitle to the subscription of nine (9) new Offer Shares. Note that it is possible to subscribe for Offer Shares also without Subscription Rights.

Subscription of shares with preferential right


1. You are being assigned subscription rights

For each held share in Eevia, one (1) Subscription Right is received on the record date Oct 27 2022.



2. How to exercise your subscription rights

Ten (10) Subscription Rights gives nine (9) Offer Shares in Eevia.



Subscription Price
1,50 SEK per share.
Record date
October 27, 2022
Subscription period
November 1-15, 2022
Trading period of subscription rights
November 1-10, 2022

Are you a directly registered shareholder of shares or do you have shares with a nominee?

<p>You have a securities account (Sw. VP-konto) (i.e. you are directly registered) and live in Sweden.</p>	→	If you exercise all Subscription Rights, the pre-printed issue statement from Euroclear Sweden should be used.
	→	If you have bought, sold, or transferred Subscription Rights to/from your securities account, fill in the application form for subscription with Subscription Rights. Payment is made in accordance with the instructions on the registration form.
<p>You have a securities account (Sw. VP-konto) (i.e. you are directly registered) and live abroad.</p>	→	See above. Payment is made in accordance with the instructions under "SHAREHOLDERS RESIDING OUTSIDE OF FINLAND AND SWEDEN" in section "Terms and conditions" in the memorandum.
<p>You have a custody account (i.e. nominee-registered shareholder)</p>	→	If you have your shares in Eevia on a custody account with a bank or other nominee, you will receive information from your nominee about the number of Subscription Rights that you have received. To subscribe, follow the instructions provided by your nominee.

Subscription of shares without Subscription Rights.

<p>You have securities account (Sw. VP-konto)</p>	→	Use the application form for subscription without Subscription Rights.
<p>You have a custody account (i.e. nominee-registered shareholder)</p>	→	Subscription and payment must be made through the respective trustee. Follow the instructions you receive from your nominees.

Note that some nominee may have a shorter application period. Check the instructions from each nominee.

Addresses

The Company

Eevia Health Plc
Koulukatu 14
FI-60100 Seinäjoki
Tel. +358 400 337 993
Finland
www.eeviahealth.com

Auditor

PricewaterhouseCoopers Oy
Itämerentori 2
00180 Helsinki
Tel. +358 (0)20 787 7000
Finland

Financial Advisor

Partner Fondkommission AB
Lilla Nygatan 2
SE-411 09 Göteborg
Tel. +46 (0) 31 16 27 80
Sweden
www.partnerfk.com

Central Securities Depository

Euroclear Sweden AB
Klarabergsviadukten 63
SE-111 64 Stockholm
Tel. +46 (0)8-402 90 00
Sweden

Euroclear Finland OY

Urho Kekkosen katu 5C
FI-00100 Helsinki
Tel. +358 (0)20 770 6000
Finland